GlassScriptPhysician profile
Willard J Niemi
NPI 1447237102
$1,118.47
in general payments reported to CMS, 2019-2025
23 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $55.25 · 2021: $151 · 2022: $114 · 2023: $142 · 2024: $161 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Travel and Lodging: $10.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.96 |
| Travel and Lodging | $10.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tricoast Surgical Solutions LLC | $164.88 | 2024-2025 | |
| Horizon Therapeutics Plc | $118.47 | 2019-2022 | |
| Organogenesis INC. | $115.42 | 2021-2025 | Apligraf, Cygnus Dual |
| Amgen INC. | $85.29 | 2024-2025 | Krystexxa |
| Abbott Laboratories | $79.73 | 2023-2024 | Proclaim, Eterna |
| Paratek Pharmaceuticals, INC. | $74.67 | 2021-2025 | Nuzyra |
| Wright Medical Technology, INC. | $55.35 | 2019 | |
| Grt US Holding, INC. | $51.08 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $41.90 | 2023 | Seglentis |
| Paragon 28, INC. | $39.60 | 2024 | Precision Mis Bunion |
| Kerecis Limited | $37.85 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Melinta Therapeutics, LLC | $33.28 | 2019 | |
| Nevro Corp. | $31.56 | 2022-2023 | Senza |
| Sebela Pharmaceuticals INC. | $27.29 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $23.53 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $22.36 | 2019 | |
| Arthrosurface Incorporated | $20.97 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.16 | 2023 | Jublia |
| Cardiovascular Systems INC. | $18.57 | 2021 | |
| Stryker Corporation | $17.32 | 2022 | |
| Averitas Pharma INC. | $13.29 | 2023 | Qutenza |
| Medtronic, INC. | $13.10 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willard Niemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.